The epidermal growth factor receptor (EGFR), which induces malignant tumour via three major mechanisms such as overexpression (Brabender et al, 2001; Hirsch et al, 2003), amplification (Shiraishi et al, 1989) and mutational activation (Downward et al, 1984), appears to be molecular target for therapeutic development. Here, EGFR is linked to cancer.